Description: Petros is committed to becoming the world's leading men's health company by identifying, developing, acquiring, and commercializing innovative therapeutics for men's health issues including, but not limited to ED, endothelial dysfunction, psychosexual and psychosocial ailments, Peyronie's disease (acute and chronic), hormone health and substance use disorders.
Home Page: www.petrospharma.com
PTPI Technical Analysis
1185 Avenue of the Americas
New York,
NY
10036
United States
Phone:
973 242 0005
Officers
| Name | Title |
|---|---|
| Mr. John D. Shulman | Exec. Chairman |
| Mr. Fady Boctor M.B.A. | Principal Exec. Officer, Pres & Chief Commercial Officer |
| Mr. Mitchell S. Arnold M.B.A. | VP of Fin. & Chief Accounting Officer |
| Mr. Robert Weinstein | Interim Chief Financial Officer |
| Mr. Keith F. Lavan | Advisor |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.2331 |
| Price-to-Sales TTM: | 1.0146 |
| IPO Date: | 2020-12-02 |
| Fiscal Year End: | December |
| Full Time Employees: | 24 |